Bacterial endocarditis following COVID-19 infection: two case reports.
COVID-19
Infective endocarditis
Secondary infection
Tocilizumab
Journal
Journal of medical case reports
ISSN: 1752-1947
Titre abrégé: J Med Case Rep
Pays: England
ID NLM: 101293382
Informations de publication
Date de publication:
16 Jun 2023
16 Jun 2023
Historique:
received:
08
01
2023
accepted:
04
05
2023
medline:
19
6
2023
pubmed:
16
6
2023
entrez:
15
6
2023
Statut:
epublish
Résumé
COVID-19, an emerging disease raised as a pandemic, urgently needed treatment choices. Some options have been confirmed as lifesaving treatments, but long-term complications must be clearly illustrated. Bacterial endocarditis is a less frequent disease among patients infected with SARS_COV_2 compared to other cardiac comorbidities in these patients. This case report discusses bacterial endocarditis as a potential adverse effect after administering tocilizumab, corticosteroids, and COVID-19 infection. In the first case, a 51-year-old Iranian female housewife was admitted to the hospital with fever, weakness, and monoarthritis symptoms. The second case is a 63-year-old Iranian woman who is a housewife admitted with weakness, shortness of breath, and extreme sweating. Both cases tested positive for Polymerase chain reaction (PCR) less than one month ago and were treated with tocilizumab and corticosteroid. Both patients were suspected of infective endocarditis. Methicillin-resistant Staphylococcus aureus (MRSA) was detected in the blood cultures of both patients. The diagnosis of endocarditis is confirmed for both cases. Cases are subjected to open-heart surgery, a mechanical valve is placed, and they are treated with medication. In subsequent visits, their condition was reported to be improving. Adjacent to cardiovascular inclusion as COVID-19 disease complications, secondary infection taken after the organisation of immunocompromising specialists can result in basic maladies and conditions counting infective endocarditis.
Sections du résumé
BACKGROUND
BACKGROUND
COVID-19, an emerging disease raised as a pandemic, urgently needed treatment choices. Some options have been confirmed as lifesaving treatments, but long-term complications must be clearly illustrated. Bacterial endocarditis is a less frequent disease among patients infected with SARS_COV_2 compared to other cardiac comorbidities in these patients. This case report discusses bacterial endocarditis as a potential adverse effect after administering tocilizumab, corticosteroids, and COVID-19 infection.
CASE PRESENTATION
METHODS
In the first case, a 51-year-old Iranian female housewife was admitted to the hospital with fever, weakness, and monoarthritis symptoms. The second case is a 63-year-old Iranian woman who is a housewife admitted with weakness, shortness of breath, and extreme sweating. Both cases tested positive for Polymerase chain reaction (PCR) less than one month ago and were treated with tocilizumab and corticosteroid. Both patients were suspected of infective endocarditis. Methicillin-resistant Staphylococcus aureus (MRSA) was detected in the blood cultures of both patients. The diagnosis of endocarditis is confirmed for both cases. Cases are subjected to open-heart surgery, a mechanical valve is placed, and they are treated with medication. In subsequent visits, their condition was reported to be improving.
CONCLUSION
CONCLUSIONS
Adjacent to cardiovascular inclusion as COVID-19 disease complications, secondary infection taken after the organisation of immunocompromising specialists can result in basic maladies and conditions counting infective endocarditis.
Identifiants
pubmed: 37322551
doi: 10.1186/s13256-023-03970-6
pii: 10.1186/s13256-023-03970-6
pmc: PMC10273726
doi:
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
274Informations de copyright
© 2023. The Author(s).
Références
Infect Dis Ther. 2021 Mar;10(1):347-362
pubmed: 33280066
Am J Case Rep. 2020 Sep 27;21:e925931
pubmed: 32980852
Int Immunopharmacol. 2020 Nov;88:106926
pubmed: 32889236
Open Heart. 2022 Mar;9(1):
pubmed: 35264415
Int J Mol Sci. 2021 Apr 06;22(7):
pubmed: 33917321
Rev Med Virol. 2021 May;31(3):e2172
pubmed: 32959951
Int J Clin Pract. 2021 Dec;75(12):e14997
pubmed: 34714574
Echocardiography. 2021 May;38(5):798-804
pubmed: 33715241
Turk Kardiyol Dern Ars. 2020 Oct;48(7):703-706
pubmed: 33034578
Eur Heart J Acute Cardiovasc Care. 2020 Dec;9(8):817-823
pubmed: 33222494
Card Electrophysiol Clin. 2022 Mar;14(1):53-62
pubmed: 35221085
Am J Ther. 2022 May-Jun 01;29(3):e275-e278
pubmed: 35249968
Med Clin (Barc). 2022 Jun 10;158(11):509-518
pubmed: 34544604
JAMA Cardiol. 2020 Jul 1;5(7):819-824
pubmed: 32219357
J Infect Public Health. 2021 Aug;14(8):1021-1027
pubmed: 34153727
JACC Cardiovasc Imaging. 2020 Nov;13(11):2480-2483
pubmed: 33153538
BMJ Case Rep. 2021 Aug 3;14(8):
pubmed: 34344645
J Autoimmun. 2020 Nov;114:102523
pubmed: 32690352
Autoimmun Rev. 2020 Jul;19(7):102564
pubmed: 32376396
Heart Rhythm. 2020 Sep;17(9):1463-1471
pubmed: 32387246
BMC Infect Dis. 2021 Nov 1;21(1):1127
pubmed: 34724920
J Glob Infect Dis. 2021 Mar 22;13(2):67-71
pubmed: 34194172
QJM. 2020 Aug 1;113(8):546-550
pubmed: 32569363
Int J Infect Dis. 2020 Sep;98:109-112
pubmed: 32574691
BMJ Case Rep. 2013 Jan 02;2013:
pubmed: 23283607
Infect Prev Pract. 2020 Sep;2(3):100080
pubmed: 34316565
Eur J Clin Invest. 2021 Nov;51(11):e13679
pubmed: 34516657
Clin Microbiol Infect. 2021 Feb;27(2):215-227
pubmed: 33161150